Search
Rizatriptan
go.drugbank.com/drugs/DB00953ApprovedInvestigational[L46018] Used in the treatment of migraines, rizatriptan was first approved in the US in 1998.
Chlortetracycline
go.drugbank.com/drugs/DB09093ApprovedVet approvedWithdrawnIt was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow.
Categories: Antibiotics for Topical Use, Antibacterials for Systemic UseGilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigational[A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.
Inosine
go.drugbank.com/drugs/DB04335ApprovedA purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose.
Linzagolix
go.drugbank.com/drugs/DB17083ApprovedInvestigational[A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627] … As these fibroids are essentially estrogen-dependent phenomena, hormone therapies which suppress estrogen activity - including GnRH receptor antagonists like linzagolix - are thought to be beneficial by
Budesonide
go.drugbank.com/drugs/DB01222ApprovedInvestigationalBudesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. Budesonide was granted FDA approval o...
Mixtures: Test Thin-Layer Rapid Use Patch TestCategories: Corticosteroids for Systemic Use, Corticosteroids for inhalation useNickel sulfate
go.drugbank.com/drugs/DB14180ApprovedNickel sulfate is used in allergenic testing.
Mixtures: Test Thin-Layer Rapid Use Patch TestProcyclidine
go.drugbank.com/drugs/DB00387ApprovedInvestigationalA muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.
Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15683ApprovedInvestigationalEVT 302
go.drugbank.com/drugs/DB06057InvestigationalEVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.